mCombriax demonstrates strong immunogenicity across age groups, exceeding comparator vaccines for multiple influenza strains and SARS-CoV-2 targets.
Medscape News Europe
Source link : https://www.medscape.com/viewarticle/first-dual-flu-covid-vaccine-mcombriax-wins-eu-approval-2026a1000ebe?src=rss
Author :
Publish date : 2026-05-05 09:36:00
Copyright for syndicated content belongs to the linked Source.
